Trial Profile
A Phase II Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients With Elevated Intraocular Hypertension
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Sep 2014
Price :
$35
*
At a glance
- Drugs MSH 1001 (Primary)
- Indications Ocular hypertension
- Focus Therapeutic Use
- Sponsors Danube Pharmaceuticals
- 19 Sep 2014 New trial record